MRI-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate

The introduction of the serum prostate-specific antigen (PSA) has changed the presentation of prostate cancer worldwide. Patients now present at a younger age, with lower grade disease, and are more likely to have organconfined cancers found upon pathologic evaluation of the radical prostatectomy specimen.1 This migration toward smaller volume disease raises the possibility of more tailored therapy.